[go: up one dir, main page]

WO2023141560A3 - Alkaline phosphatase for use in oncology - Google Patents

Alkaline phosphatase for use in oncology Download PDF

Info

Publication number
WO2023141560A3
WO2023141560A3 PCT/US2023/060978 US2023060978W WO2023141560A3 WO 2023141560 A3 WO2023141560 A3 WO 2023141560A3 US 2023060978 W US2023060978 W US 2023060978W WO 2023141560 A3 WO2023141560 A3 WO 2023141560A3
Authority
WO
WIPO (PCT)
Prior art keywords
oncology
cancer therapy
alkaline phosphatase
iap
laps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/060978
Other languages
French (fr)
Other versions
WO2023141560A2 (en
Inventor
Michael Kaleko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theriva Biologics Inc
Original Assignee
Synthetic Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Biologics Inc filed Critical Synthetic Biologics Inc
Publication of WO2023141560A2 publication Critical patent/WO2023141560A2/en
Publication of WO2023141560A3 publication Critical patent/WO2023141560A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates, inter alia, to combination therapies of specific commensal gastrointestinal bacteria with therapeutic intestinal alkaline phosphatases (lAPs) for preventing, treating, and/or reducing a cancer therapy-mediated side effect, or improving efficacy of a cancer therapy relative to the treatment before or in the absence of IAP.
PCT/US2023/060978 2022-01-20 2023-01-20 Alkaline phosphatase for use in oncology Ceased WO2023141560A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263301227P 2022-01-20 2022-01-20
US63/301,227 2022-01-20

Publications (2)

Publication Number Publication Date
WO2023141560A2 WO2023141560A2 (en) 2023-07-27
WO2023141560A3 true WO2023141560A3 (en) 2023-09-21

Family

ID=87349170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060978 Ceased WO2023141560A2 (en) 2022-01-20 2023-01-20 Alkaline phosphatase for use in oncology

Country Status (1)

Country Link
WO (1) WO2023141560A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4568749A1 (en) * 2022-08-09 2025-06-18 Theriva Biologics, Inc. Treatment or prevention of gastrointestinal immunotherapy side effects

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106983A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
WO2020163381A1 (en) * 2019-02-04 2020-08-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to detect gastrointestinal disease
US20200277379A1 (en) * 2019-03-01 2020-09-03 Rampart Health, L.L.C. Pharmaceutical composition combining immunologic and chemotherapeutic method for the treatment of cancer
WO2020247421A1 (en) * 2019-06-03 2020-12-10 Synthetic Biologics, Inc. Alkaline phosphatase formulations and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106983A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
WO2020163381A1 (en) * 2019-02-04 2020-08-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to detect gastrointestinal disease
US20200277379A1 (en) * 2019-03-01 2020-09-03 Rampart Health, L.L.C. Pharmaceutical composition combining immunologic and chemotherapeutic method for the treatment of cancer
WO2020247421A1 (en) * 2019-06-03 2020-12-10 Synthetic Biologics, Inc. Alkaline phosphatase formulations and uses thereof

Also Published As

Publication number Publication date
WO2023141560A2 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
IL171607A (en) Use of a botulinum toxin for the preparation of a medicament for treating sinus headache
PT1165108E (en) USE OF AN EXTRACT FROM SERENOA REPENS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF PROSTATE CANCER.
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
CA2265547A1 (en) Method of treating endothelial injury
ZA202304965B (en) Combination therapy for treating cancer
WO2023141560A3 (en) Alkaline phosphatase for use in oncology
MX2023006793A (en) Combination therapies for treatment of her2 cancer.
MX2009011320A (en) Enzymatic anticancer therapy.
IL315153A (en) Combination therapies for breast cancer
IL319182A (en) Deuterium-enriched pirfenidone and methods of use thereof
WO2021007314A3 (en) Treatment of cancer
MX2022006155A (en) Lung targeted anticancer therapies with liposomal annamycin.
MX2022014886A (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy.
IL312037A (en) Endoxifen for the treatment of cancer
MX2025002967A (en) Pharmaceutical composition and use thereof
MX2022011171A (en) Compounds with immunomodulatory activity and therapeutic uses thereof.
ZA202406390B (en) Compounds and their use in treating cancer
WO2024097446A3 (en) Theranostic compounds targeting granzyme b
WO2024249769A3 (en) Combination therapy for treating hematological cancers
WO2023164455A3 (en) Compositions and methods to modulate the immune system
IL159770A0 (en) Calcium salts with cytotoxic activity
Brizel et al. 6 Final report of a phase III randomized trial of amifostine as a radioprotectant in head and neck cancer
Nakazato et al. An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer
TW200724158A (en) Combination therapy in the treatment of cancer
WO2025188783A8 (en) Therapeutic compositions and methods for treating cancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23743945

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23743945

Country of ref document: EP

Kind code of ref document: A2